Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
about
Serotonin inhibits low-threshold spike interneurons in the striatumSelective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNSStriatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?Age-related alterations in the expression of genes and synaptic plasticity associated with nitric oxide signaling in the mouse dorsal striatumReview: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibitionPhosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonismNeuronal nitric oxide contributes to neuroplasticity-associated protein expression through cGMP, protein kinase G, and extracellular signal-regulated kinase.Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionEndocannabinoid-dopamine interactions in striatal synaptic plasticity.Sildenafil promotes neuroprotection of the pelvic ganglia neurones after bilateral cavernosal nerve resection in the rat.Endocannabinoids in striatal plasticity.Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsNew synaptic and molecular targets for neuroprotection in Parkinson's disease.Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.Motor cortical plasticity in Parkinson's disease.The pathomechanisms underlying Parkinson's disease.Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indicationsDopaminergic modulation of striatal networks in health and Parkinson's disease.Molecular imaging of levodopa-induced dyskinesias.Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia.Hyperkinetic disorders and loss of synaptic downscaling.Phosphodiesterase 10 inhibitors in clinical development for CNS disorders.Modulation of the ASK1-MKK3/6-p38/MAPK signalling pathway mediates sildenafil protection against chemical hypoxia caused by malonate.Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats.Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.Mutual Control of Cholinergic and Low-Threshold Spike Interneurons in the Striatum.Interneuronal Nitric Oxide Signaling Mediates Post-synaptic Long-Term Depression of Striatal Glutamatergic Synapses.Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia.PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases.Nitric Oxide-Soluble Guanylyl Cyclase-Cyclic GMP Signaling in the Striatum: New Targets for the Treatment of Parkinson's Disease?Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice.Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
P2860
Q24614161-1A91A760-33D2-4D5D-9704-3226551E7E4EQ24629746-4EB56D2B-4E58-4D80-8BD0-582EB309A6BBQ26768220-4B2B201C-A60B-4E84-9391-4E46FB2F9AB5Q27002626-86C1BBBA-0659-4482-BAA9-5ACA47C2FFDBQ28390090-984FCBF2-8933-47E0-990F-C6CE99852085Q28394979-A6CF2245-044F-48AC-81B5-1D27DC80EBE6Q33624262-699735B1-75DB-4941-B7F9-5FAC6EBF1953Q35028568-CCFC1220-E0AD-475F-8BFA-C68EF609011BQ35033344-FB41796B-3ACE-4E36-8D4C-EB13AA5875E1Q35307838-2897280D-EE44-4D27-B363-5D9D1743C9A5Q35424424-839A6BC3-0BEB-47E8-8661-9E5031010377Q35499568-37163F0A-306E-4664-A894-913E4D2FA5E3Q35898412-02D058A8-787B-4AD0-8825-4802B93573DCQ36542393-910C242F-6B9E-4484-B9D7-B8AA3A619957Q36686382-2863D150-C605-42A4-B7C4-DCFC691FC9A4Q37183072-31BD5577-16D9-4B9C-8387-9CF6166B2FD9Q38038559-062726B8-73B6-407C-B4B6-57323619BF62Q38063779-849B906B-52DE-485B-868D-68E215D73403Q38101499-6E41B420-4087-4D2B-947A-84FF9E85F6B6Q38136650-BAD875C6-8189-4DB1-B266-38C2CD6A2989Q38182660-7DDEA7F0-8D6C-485E-9173-AB2268F5877AQ38209092-C82E3C3D-E335-4AF7-8629-582779782838Q38233462-0EA997C0-F4C9-415F-92DA-E3DBF15B94B2Q38355582-44D9FB8A-01C6-49A4-BF77-AD44A10D4128Q38479031-88C69408-878E-4A52-A656-C19B96E7B277Q38847727-771E4BA2-B507-4888-8688-7285684CA2D4Q39029199-DAEE6466-D40A-45AB-BCEE-A09BBC0477C3Q39759995-4BFDB6FC-2BD1-4ACA-A993-EDC84FAEA7BDQ40313187-16B767D3-1DB2-4C6A-AB92-7ECE695C9BDEQ40696539-191E6D1B-F643-4F6C-BCA4-C377A07906C3Q40785212-10E3ECC2-73A5-4B23-B5EF-B7C59154D3DBQ41412530-D1FF0B6C-693F-4E97-A072-E7D58C110EE7Q41584434-8809C526-0EBF-4ED6-BAB0-3EC1D9D9D481Q42177230-AD9974F7-3182-4275-8525-0284ABFE514FQ42369736-71D374A2-A267-46B1-B8BC-E216FACEA9B0Q42495608-420E4864-18BC-4D00-85CA-6EEEC848C090Q42785592-FD6F21C4-7EBB-4C73-813F-2824B61C4B00Q46986165-575B8E56-DAB3-4FBA-BB18-9F89BF27D632Q47909580-F531DD79-8508-422F-B7B4-34007372EC6EQ48093702-6145833A-3BAF-4F44-8EBA-06CE5B62DD58
P2860
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Inhibition of phosphodiesteras ...... s levodopa-induced dyskinesia.
@en
Inhibition of phosphodiesteras ...... s levodopa-induced dyskinesia.
@nl
type
label
Inhibition of phosphodiesteras ...... s levodopa-induced dyskinesia.
@en
Inhibition of phosphodiesteras ...... s levodopa-induced dyskinesia.
@nl
prefLabel
Inhibition of phosphodiesteras ...... s levodopa-induced dyskinesia.
@en
Inhibition of phosphodiesteras ...... s levodopa-induced dyskinesia.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
Inhibition of phosphodiesteras ...... es levodopa-induced dyskinesia
@en
P2093
Carmela Giampà
Francesca R Fusco
Massimiliano Di Filippo
Paolo Calabresi
Valentina Pendolino
Vincenza Bagetta
P2860
P304
P356
10.1093/BRAIN/AWQ342
P407
P577
2010-12-22T00:00:00Z